Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809

Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA

Riordan, J. R., Rommens, J. M., Kerem, B.-S., Alon, N., Rozmahel, R., Grzelczak, Z., Zielenski, J., Lok, S., Plavsic, N., Chou, J.-L., et al. (1989) · Science · doi:10.1126/science.2475911 · Cited by 7,418

Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis

Cheng, S. H., Gregory, R. J., Marshall, J., Paul, S., Souza, D. W., White, G. A., O’Riordan, C. R., & Smith, A. E. (1990) · Cell · doi:10.1016/0092-8674(90)90148-8 · Cited by 1,792

Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive

Denning, G. M., Anderson, M. P., Amara, J. F., Marshall, J., Smith, A. E., & Welsh, M. J. (1992) · Nature · doi:10.1038/358761a0 · Cited by 1,236

Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770

Goor, F. V., Hadidaꝉ, S., Grootenhuis, P. D. J., Burton, B., Cao, D., Neuberger, T., Turnbull, A., Singh, A. K., Joubran, J., Hazlewood, A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904709106 · Cited by 1,225

Guidelines for Diagnosis of Cystic Fibrosis in Newborns through Older Adults: Cystic Fibrosis Foundation Consensus Report

Farrell, P. M., Rosenstein, B. J., White, T. B., Accurso, F. J., Castellani, C., Cutting, G. R., Durie, P. R., LeGrys, V. A., Massie, J., Parad, R. B., et al. (2008) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2008.05.005 · Cited by 1,093

Cystic fibrosis: A worldwide analysis ofCFTR mutations?correlation with incidence data and application to screening

Bobadilla, J. L., Macek, M., Fine, J. P., & Farrell, P. M. (2002) · Human Mutation · doi:10.1002/humu.10041 · Cited by 1,032

Effect of VX-770 in Persons with Cystic Fibrosis and the G551D- CFTR Mutation

Accurso, F. J., Rowe, S. M., Clancy, J. P., Boyle, M., Dunitz, J., Durie, P. R., Sagel, S. D., Hornick, D. B., Konstan, M. W., Donaldson, S. H., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909825 · Cited by 803

Altered chloride ion channel kinetics associated with the ΔF508 cystic fibrosis mutation

Dalemans, W., Barbry, P., Champigny, G., Jallat, S., Jallat, S., Dott, K., Dreyer, D., Crystal, R. G., Pavirani, A., Lecocq, J.-P., et al. (1991) · Nature · doi:10.1038/354526a0 · Cited by 707

Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice

Castellani, C., Cuppens, H., Maçek, M., Cassiman, J. J., Kerem, E., Durie, P. R., Tullis, E. D., Assael, B. M., Bombieri, C., Brown, A., et al. (2008) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2008.03.009 · Cited by 624

Small-molecule correctors of defective F508-CFTR cellular processing identified by high-throughput screening

Pedemonte, N. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24898 · Cited by 551

Ion Channels

Townsend, C. Y. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.99998-5 · Cited by 1

Efficacy of triple targeted therapy against chronic rhinosinusitis in children with cystic fibrosis (case series)

Polyakov, D. P., Kondratyeva, E., Voronkova, A. Y., & Ramazanova, P. I. (2023) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2023-399 · Cited by 1

Ivacaftor ameliorates mucus burden, bacterial load, and inflammation in acute but not chronic P. aeruginosa infection in hG551D rats

Keith, J. D., Murphree-Terry, M., Bollar, G. E., Oden, A. M., Doty, I. H., & Birket, S. E. (2024) · Respiratory Research · doi:10.1186/s12931-024-03029-0 · Cited by 1

Toward in vivo bronchoscopic functional CFTR assessment using a short circuit current measurement probe

Otuya, D. O., Liu, Z., Joseph, R., Hanafy, M. A., Vijaykumar, K., Stanford, D. D., Raju, S. V., Baker, E. H., Rowe, S. M., Tearney, G. J., et al. (2024) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00137.2024 · Cited by 1

A novel gene therapy for ARPKD based on CFTR

Ciobanu, C., Outeda, P., Guggino, W. B., & Cebotaru, L. (2025) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00109.2025 · Cited by 1

Catalytic region mimetics in Na+/H+ exchanger regulatory factor 4 suppress guanylate cyclase 2C activity to regulate enterotoxin triggered diarrhea

Ramananda, Y., Liyanage, P. S., Huang, Y., Porollo, A., Hannig, G., Naren, A. P., & Arora, K. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110559 · Cited by 1

Comparison of the Effect of CFTR Modulators elexacaftor/tezacaftor/ivacaftor and lumacaftor/ivacaftor via Serum Human Epididymis Protein 4 Concentration in p.Phe508del-CFTR Homozygous Cystic Fibrosis Patients

Pócsi, M., Fila, L., Péterfia, C., Halász, A., Szanto, T. G., Mészáros, B., Major, J., Laki, I., Szabó, H., Panyi, G., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14176188 · Cited by 1

Transformative Research in Cystic Fibrosis

Sorscher, E. J. (2025) · New England Journal of Medicine · doi:10.1056/nejmcibr2510197 · Cited by 1

CFTR correctors potentiate gating mutants causing cystic fibrosis

Castanier, S., Elbahnsi, A., Chevalier, B., Berri, L., Wickramanayaka, M. D., Mornon, J., Hatton, A., Sermet‐Gaudelus, I., Edelman, A., Callebaut, I., et al. (2025) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2025.11.008 · Cited by 1

Reflection confocal microscopy for quantitative assessment of airway surface layer dysregulation and pharmacological rescue in cystic fibrosis under near-physiological conditions

Agircan, A. S., Lampe, M., Scheuermann, H., Albrecht, T., Graeber, S. Y., Balázs, A., Baumann, I. G., Block, S., Pepperkok, R., Mall, M. A., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-32061-3 · Cited by 1

RFFL-mediated protein quality control limits functional rescue of TRID-CFTR modulator combination therapy for cystic fibrosis nonsense mutations

Tateishi, H., Doi, Y., Kamada, Y., & Okiyoneda, T. (2026) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-026-06114-3 · Cited by 1

CFTR modulator monotherapy for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del)

Heneghan, M., Smith, S. J., Jahnke, N., Nevitt, S. J., Southern, K. W., & supported by the Cochrane Cystic Fibrosis Review Group (2026) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd016290 · Cited by 1

Predictive capacity of paediatric nasal epithelial cells in sequential CFTR modulator therapy

Fawcett, L. K., Chew, Z. A., Schneider‐Futschik, E. K., Allan, K. M., Patel, H. R., Jaffé, A., & Waters, S. A. (2025) · Thorax · doi:10.1136/thorax-2025-223153 · Cited by 2

Real-life effectiveness and safety of lumacaftor/ivacaftor in preschool children with cystic fibrosis: data from an italian multicentre study

Presti, S., Cimbalo, C., Terminiello, A., Fevola, C., Daccò, V., Sepe, A., Troiani, P., Casciaro, R., Dio, N. D., Castellani, C., et al. (2026) · Pediatric Research · doi:10.1038/s41390-026-05121-1 · Cited by 1

Integrated Screening Cascades for Ion-Channel Drug Discovery: Linking Structure, Electrophysiology, Safety Pharmacology, and Human-Relevant Models

Seo, Y. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135774 · Cited by 1

Medications to Enhance CFTR Activity

Chin, T. W. (2015) · InTech eBooks · doi:10.5772/60768 · Cited by 1

Profile of lumacaftor/ivacaftor combination: potential in the treatment of cystic fibrosis

Pettit, R. S., & Arends, A. (2015) · Orphan Drugs Research and Reviews · doi:10.2147/odrr.s78413 · Cited by 1

Salty sea regulators of cystic fibrosis

Gupta, V. R., & Balch, W. E. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.1144 · Cited by 2

Predicting CFTR activity with front-runner cystic fibrosis drugs

Becq, F. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.01.013 · Cited by 1

Pharmacogenomics: mapping monogenic mutations to direct therapy

Taylor, P. (2012) · Journal of Clinical Investigation · doi:10.1172/jci64409 · Cited by 1

CFTR Modulator Therapies for Cystic Fibrosis

Trimble, A. T., & Donaldson, S. H. (2015) · Pediatric Allergy Immunology and Pulmonology · doi:10.1089/ped.2015.0583 · Cited by 1

The Discovery of Novel Inhaled ENaC Blockers for the Treatment of Cystic Fibrosis Lung Disease

Howsham, C., & Danahay, H. L. (2014) · Royal Society of Chemistry eBooks · doi:10.1039/9781849735087-00135 · Cited by 1

The Therapeutic Potential of Small-molecule Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Cl− Channel

Liu, J., Cami‐Kobeci, G., Wang, Y., Khuituan, P., Cai, Z., Li, H., Husbands, S. M., & Sheppard, D. N. (2014) · Royal Society of Chemistry eBooks · doi:10.1039/9781849735087-00156 · Cited by 1

sidebar: Cystic Fibrosis: A Model for Personalized Genetic Medicine

Green, D. (2013) · North Carolina Medical Journal · doi:10.18043/ncm.74.6.486 · Cited by 1

Multiscale Mathematical Modeling of the Absorptive and Mucociliary Pathophysiology of Cystic Fibrosis Lung Disease

Markovetz, M. R. (2017) · D-Scholarship@Pitt (University of Pittsburgh) · Cited by 1

Complexity of phenotypes induced by p.Asn1303Lys-CFTR correlates with difficulty to rescue and activate this protein

Farhat, R. D., El-Seedy, A. S., Norez, C., Hugo Talbot, A., Pasquet, M.-C., Adolphe, C., Kitzis, A., & Ladevèze, V. (2017) · Cellular and Molecular Biology · doi:10.14715/cmb/2017.63.11.18 · Cited by 1

Trafficking and Quality Control of Inward-Rectifying Potassium Channels in the Model Eukaryote Saccharomyces cerevisiae

Mackie, T. D. (2018) · D-Scholarship@Pitt (University of Pittsburgh) · Cited by 1

Overview of CFTR Modulators and Gene Therapy

Rang, C., Kotsimbos, T. C., & Wilson, J. W. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.91022 · Cited by 2

Cystic Fibrosis and Chronic Rhinosinusitis: Interventions on the Horizon

Banks, C. G., Thompson, H. M., Grayson, J. W., Cho, D., & Woodworth, B. A. (2020) · Springer eBooks · doi:10.1007/978-3-030-50330-7_10 · Cited by 1

PROGRESOS EN FARMACOTERAPIA EN FIBROSIS QUÍSTICA

Córdova, F. V., & Pizarro, M. E. (2021) · Neumología Pediátrica · doi:10.51451/np.v13i3.209 · Cited by 1

Target Validation—Prosecuting the Target

Jones, L. H. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00014-1 · Cited by 1

A clinical case of cystic fibrosis patient with pathogenic N1303K genotype variant with assessment of the CFTR channel function by intestinal current measurement and forskolin-induced swelling in rectal organoids

Kondratyeva, E., Odinaeva, N. D., Sherman, V. D., Efremova, A. S., Melyanovskaya, Y. L., Bulatenko, N., Bukharova, T. B., & Goldshtein, D. V. (2021) · Almanac of Clinical Medicine · doi:10.18786/2072-0505-2021-49-019 · Cited by 1

Review of the British Thoracic Society Winter Meeting 2011, 7–9 December, London, UK

Bayes, H. K., Church, A. C., & Fisher, A. J. (2012) · Thorax · doi:10.1136/thoraxjnl-2012-201597 · Cited by 1

In vitroassessment of triple combination therapy for the most common disease-associated mutation in cystic fibrosis

Yeh, H., & Hwang, T. (2022) · European Respiratory Journal · doi:10.1183/13993003.02380-2021 · Cited by 1

Symposium Summaries

(2017) · Pediatric Pulmonology · doi:10.1002/ppul.23839 · Cited by 1

From Calcium Channels to New Therapeutics

McDonough, S. I. (2022) · Springer eBooks · doi:10.1007/978-3-031-08881-0_27 · Cited by 1

Lessons from other fields of medicine, Part 2: Cystic fibrosis

Vijaykumar, K., & Rowe, S. M. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85538-9.00006-7 · Cited by 1

Cystic Fibrosis Modulator Therapies: Bridging Insights from CF to other Membrane Protein Misfolding Diseases

Kim, M., & Plate, L. (2024) · Israel Journal of Chemistry · doi:10.1002/ijch.202300152 · Cited by 1

Amelioration of airway and GI disease in G551D-CF ferrets by AAV1 and AAV6

Ciobanu, C., Yanda, M. K., Zeidan, A., Izzi, J. M., Guggino, W. B., & Cebotaru, L. (2024) · Gene Therapy · doi:10.1038/s41434-024-00469-7 · Cited by 1

Respiratory Outcomes of Interrupted Modulator Therapies in Children With Cystic Fibrosis

Öztosun, B., Başkan, A. K., Arslan, H., Korkmaz, C., Çollak, A., Çokuğraş, H. C., & Kılınç, A. A. (2024) · Pediatric Pulmonology · doi:10.1002/ppul.27390 · Cited by 1

Acquired cystic fibrosis transmembrane conductance regulator dysfunction

Eisenhut, M., & Wallace, H. L. (2025) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-025-03127-y · Cited by 1

TRPML Channels and Mucolipidosis Type IV

Grimm, C. M., & Cuajungco, M. P. (2013) · Springer eBooks · doi:10.1007/978-3-642-40282-1_19 · Cited by 1

Natural Compounds as Therapeutic Agents to Treat Cystic Fibrosis

Bradbury, N. A., Dey, I., & Shah, K. (2016) · Cited by 1

A Review of Treatments That Improve Cystic Fibrosis Transmembrane Conductance Regulator Function

Shanthikumar, S., & Massie, J. (2017) · doi:10.4137/cmt.s38624 · Cited by 1

Buserelin alleviates chloride transport defect in human cystic fibrosis nasal epithelial cells

Calvez, M.-L., Benz, N., Huguet, F., Saint-Pierre, A., Rouillé, E., Coraux, C., Férec, C., Kerbiriou, M., & Trouvé, P. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187774 · Cited by 1

The role of stem cells in cystic fibrosis disease modeling and drug discovery

Conese, M., Beccia, E., Carbone, A., Castellani, S., Gioia, S. D., Corti, F., Angiolillo, A., & Colombo, C. (2018) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2018.1549480 · Cited by 1

Cystic Fibrosis: Biology and Therapeutics

Verma, P., Vishwakarma, V. K., Paswan, S. K., Rao, C. V., & Srivastava, S. (2020) · Springer eBooks · doi:10.1007/978-981-15-3734-9_3 · Cited by 1

Human genetic diversity in health and disease

Rankov, A. D., & Ljujić, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819541-3.00008-6 · Cited by 1

Cystic Fibrosis and Genotype-Dependent Therapy: Is There a Need for a Sex-Specific Therapy?

Bradbury, N. A. (2020) · Gender and the Genome · doi:10.1177/2470289720937025 · Cited by 1

Vardenafil increases intracellular accumulation of the most prevalent mutant CFTR in human bronchial epithelial cells

Dhooghe, B., Bouzin, C., Mottais, A., Hermans, E., Delion, M. F., Panin, N., Noël, S., & Leal, T. (2020) · Biology Open · doi:10.1242/bio.053116 · Cited by 1

Membrane Protein Structure and Folding

Zheng, A., Frizzell, S. C., Klombers, S., & Thibodeau, P. H. (2020) · Physiology in health and disease · doi:10.1007/978-3-030-52780-8_6 · Cited by 1

The march towards CFTR modulator access for all people with CF: The end of the beginning

VanDevanter, D. R. (2021) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2021.01.005 · Cited by 1

Diseases of the Pancreas Involving Channels/Transporters

Blobner, B. M., & Whitcomb, D. C. (2020) · Physiology in health and disease · doi:10.1007/978-3-030-55310-4_4 · Cited by 1

Targeted Therapeutics for Rare Disorders

Keeling, K. M., Leier, A., Bedwell, D. M., Chen, A. T., Kesterson, R. A., Marquez‐Lago, T. T., Müller, U. F., Zhou, J., Popplewell, L. J., & WALLIS, D. E. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824010-6.00009-5 · Cited by 1

Using the genome to correct the ion transport defect in cystic fibrosis

Amaral, M. D. (2022) · The Journal of Physiology · doi:10.1113/jp282308 · Cited by 1

Recovery of ΔF508-CFTR Function by Citrate

Borkenhagen, B., & Prehm, P. (2022) · Nutrients · doi:10.3390/nu14204283 · Cited by 1

The Evidence for Long-Term Benefits of Restoration of CFTR Function Continues to Grow

Boyle, M. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201507-1348ed · Cited by 1

Cystic Fibrosis: Passion, perception and education

Fitzgerald, D. A. (2013) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2013.11.010 · Cited by 1

CFTR corrector efficacy is associated with occupancy of distinct binding sitesPreprint

Baatallah, N., Elbahnsi, A., Mornon, J., Chevalier, B., Pranke, I. M., Servel, N., Zelli, R., Décout, J., Edelman, A., Sermet‐Gaudelus, I., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.04.442442 · Cited by 1

Cystic Fibrosis

Bradbury, N. A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821618-7.00159-0 · Cited by 1

Computational analysis of long-range allosteric communications in CFTRPreprint

Ayca, E., Altintel, B., Nurit, L. L., Ben‐Tal, N., Haliloǧlu, T., & Lewinson, O. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.07.543997 · Cited by 1

Computational analysis of long-range allosteric communications in CFTRPreprint

Ayca, E., Altintel, B., Nurit, L. L., Ben‐Tal, N., Haliloǧlu, T., & Lewinson, O. (2023) · eLife · doi:10.7554/elife.88659.2 · Cited by 1

Editorial: Mechanisms of action of small molecules on CFTR mutants and the impact on cystic fibrosis pathogenesis

Ehré, C., Lopes‐Pacheco, M., & Laselva, O. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1446875 · Cited by 1

The Role of Chemical Biology in Understanding and Treating Disease‐Are Small Molecule “Correctors” the Way of the Future?

Selwood, D. L. (2012) · Chemical biology · doi:10.1002/9781118435762.ch11

Mammalian Cell Cultures: The Example of Airway Epithelial Cell Cultures for Cystic Fibrosis Research

Randell, S. H. (2012) · doi:10.1002/9781118402184.ch6

Sponging out cystic fibrosis

Osherovich, L. Z. (2012) · Science-Business eXchange · doi:10.1038/scibx.2012.1200

Rationalizing CF combos

Cain, C. (2013) · Science-Business eXchange · doi:10.1038/scibx.2013.589

Highlights of the 28th North American Cystic Fibrosis Conference 2014

Nwokoro, C. E. C. (2015) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2015.07.009

A new book “Rare Diseases: Integrative PPPM Approach as the Medicine of the Future”

Özgüç, M. (2014) · The EPMA Journal · doi:10.1186/1878-5085-5-s1-a16

Role of Chemical Biology in Understanding and Treating Disease

Selwood, D. L. (2012) · Wiley Encyclopedia of Chemical Biology · doi:10.1002/9780470048672.wecb723

Review of the British Thoracic Society Winter Meeting 2012, 5 to 7 December, London, UK

Bayes, H. K., Church, A. C., & Fisher, A. J. (2013) · Thorax · doi:10.1136/thoraxjnl-2012-203165

A cocktail drug therapy for patients with cystic fibrosis?

Chen, J.-H. (2014) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2014.07.002

Prenatal Diagnosis of Cystic Fibrosis

Grody, W. W. (2015) · Wiley eBooks · doi:10.1002/9781118981559.ch17

Development of Cystic Fibrosis Transmembrane Regulator Therapies

Darbishire, P. L. (2012) · Journal of Developing Drugs · doi:10.4172/2329-6631.1000e117

Recent disclosures of clinical candidates - Highlights from the Society for Medicines Research Symposium, held on December 8, 2011 at The National Heart and Lung Institute, South Kensington, London, UK

ALDERTON, W. K., Collingwood, S. P., & Ratcliffe, A. J. (2012) · Drugs of the Future · doi:10.1358/dof.2012.037.03.1782930

Small Molecules that Rescue F508del CFTR as Cystic Fibrosis Therapies

Pregel, M. J. (2014) · Royal Society of Chemistry eBooks · doi:10.1039/9781782624202-00230

α 1 -antitrypsin deficiency

Bruce-Hickman, D., Greene, C. M., & Gooptu, B. (2015) · European Respiratory Society eBooks · doi:10.1183/2312508x.10018214 · Cited by 1

Diseases of the Pancreas Involving Channels/Transporters

Whitcomb, D. C. (2015) · Springer eBooks · doi:10.1007/978-1-4939-3366-2_28

PULMONARY, SLEEP, AND CRITICAL CARE UPDATE Update in Cystic Fibrosis 2014

Ong, T., & Ramsey, B. W. (2015)

Pharmacogenomics: mapping monogenic mutations to direct therapy

Moe, O. W. (2012)

Nanotechnology approach for treatment of cystic fibrosis

Kbah, N. (2016) · doi:10.7282/t3df6t83

Macrophage Polarization and Function in Cystic Fibrosis

Tarique, A. A. (2016) · The University of Queensland · doi:10.14264/uql.2016.680 · Cited by 1

Structural Basis for Misfolding at Disease Phenotypic Positions in CFTR

Mulvihill, C. M. (2012) · TSpace (University of Toronto)

CFTR Modulator Therapies in Cystic Fibrosis

Spielberg, D. R., Clancy, J. P., & Siracusa, C. M. (2017) · Milestones in drug therapy · doi:10.1007/978-3-0348-0977-1_6

Short Palate Lung and Nasal Epithelium Clone 1 Dissociates and Endocytoses the Epithelial Sodium Channel

Kim, C. S. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/yxw4-y262

Protein Repair

Espel, J. C., & Jain, M. (2015) · Clinical Pulmonary Medicine · doi:10.1097/cpm.0000000000000121

CFTR functional assays in drug development

Zak, S. M., Clancy, J. P., & Brewington, J. J. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2017.1393413

Structural Basis Of Membrane Protein Scaffolding And Signaling In Human Disease

Holcomb, J. (2017) · Human Biology

Quality before Quantity: Inspecting CFTR

Mou, H. (2018) · Developmental Cell · doi:10.1016/j.devcel.2018.03.003

Cystic fibrosis transmembrane conductance regulator modulators

Clancy, J. P. (2013) · doi:10.2217/ebo.12.522

Enhancing the Efficiency of CRISPR/Cas9 Precise Gene Editing for Cystic Fibrosis Gene Therapy

Seigel, K. E. (2018) · TSpace (University of Toronto)

THE MOLECULAR ETIOLOGY OF ATYPICAL CYSTIC FIBROSIS & PHENOTYPIC HETEROGENEITY IN CLASSIC CYSTIC FIBROSIS

Vecchio-Pagán, B. (2016)

Cystic Fibrosis: New Insights into Therapeutic Approaches

Tosco, A., Villella, V. R., Raia, V., Kroemer, G., & Maiuri, L. (2019) · Current Respiratory Medicine Reviews · doi:10.2174/1573398x15666190702151613

Case report of an unexpected reaction associated with Lumacaftor/ivacaftor therapy for cystic fibrosis

Farrell, C., Coleman, S., & Casserly, B. P. (2019) · doi:10.36811/ojprm.2019.110003

Multi-Scale Mathematical Models of Airway Epithelium to Facilitate Cystic Fibrosis Treatment

Castillo, F. S. (2019) · D-Scholarship@Pitt (University of Pittsburgh)

Infrared biomarkers of impaired cystic fibrosis transmembrane regulator protein biogenesis

Bellisola, G., Caldrer, S., Guidi, M. C., & Cinque, G. (2019) · Journal of Biophotonics · doi:10.1002/jbio.201900174

Hsp90: A Target for Susceptibilities and Substitutions in Biotechnological and Medicinal Application

Warnecke, A., Kirschning, A., Landsberg, D., & Zeilinger, C. (2019) · Heat shock proteins · doi:10.1007/978-3-030-23158-3_18 · Cited by 1

Elexacaftor-tezacaftor-ivacaftor—A Combination Therapy for Phe508del Cystic Fibrosis

Jia, S., Taylor‐Cousar, J. L., & National Jewish Health, D. (2019) · touchREVIEWS in Respiratory & Pulmonary Diseases · doi:10.17925/usprd.2019.4.1.15

Cystic fibrosis in the era of effective treatment: Informing targeted therapy and influencing reproductive decision-making

McCague, A. F. (2019)

Genetic Mutations in CFTR Protein Gene Cause Cystic Fibrosis- Its Symptoms, Treatment, and Incidence in Pakistan

Sabar, M. F., & Arshad, F. (2019) · Haya The Saudi Journal of Life Sciences · doi:10.36348/sjls.2019.v04i08.005

Increased efficacy of VX ‐809 in different cellular systems results from an early stabilization effect of F508del‐ CFTR

Farinha, C. M., Sousa, M., Canato, S., Schmidt, A., Uliyakina, I., & Amaral, M. D. (2015) · Pharmacology Research & Perspectives · doi:10.1002/prp2.152 · Cited by 43

Pharmacological Correction of Cystic Fibrosis: Molecular Mechanisms at the Plasma Membrane to Augment Mutant CFTR Function

Arora, K., & Naren, A. P. (2016) · Current Drug Targets · doi:10.2174/1389450117666151209114343 · Cited by 11

Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors

Amico, G., Brandas, C., Morán, Ó., & Baroni, D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215463 · Cited by 27

Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment

Capurro, V., Tomati, V., Sondo, E., Renda, M., Borrelli, A., Pastorino, C., Guidone, D., Venturini, A., Giraudo, A., Bertozzi, S. M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105262 · Cited by 72

Revertants, Low Temperature, and Correctors Reveal the Mechanism of F508del-CFTR Rescue by VX-809 and Suggest Multiple Agents for Full Correction

Farinha, C. M., King-Underwood, J., Sousa, M., Correia, A. R., Henriques, B. J., Roxo‐Rosa, M., Paula, A. C. D., Williams, J. P., Hirst, S., Gomes, C. M., et al. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.06.004 · Cited by 164